WO2001090717A2 - Bras de liaison pour nanocristaux et composes correspondants - Google Patents

Bras de liaison pour nanocristaux et composes correspondants Download PDF

Info

Publication number
WO2001090717A2
WO2001090717A2 PCT/US2001/016947 US0116947W WO0190717A2 WO 2001090717 A2 WO2001090717 A2 WO 2001090717A2 US 0116947 W US0116947 W US 0116947W WO 0190717 A2 WO0190717 A2 WO 0190717A2
Authority
WO
WIPO (PCT)
Prior art keywords
nanocrystal
compound
derivatives
group
nanocrystals
Prior art date
Application number
PCT/US2001/016947
Other languages
English (en)
Other versions
WO2001090717A3 (fr
Inventor
Sandra J. Rosenthall
Ian D. Tomlinson
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to AU2001266609A priority Critical patent/AU2001266609A1/en
Publication of WO2001090717A2 publication Critical patent/WO2001090717A2/fr
Publication of WO2001090717A3 publication Critical patent/WO2001090717A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots

Definitions

  • This invention generally relates to nanocrystals, linker arms for nanocrystals, and compounds resulting therefrom.
  • this invention relates to labeling techniques using the compounds of the present invention.
  • Fluorescent nanocrystal labeling has broad application in the biomedical sciences.
  • the labeling technique of the present invention provides improved and widely applicable methods for detecting biomolecules and for scrutinizing biomolecular processes.
  • Quantum dots are being used as fluorescent tags capable of tracing specific substances within cells. Quantum dots can be activated to glow with different colors, so it is easier to use quantum dots in tandem than combinations of conventional fluorescent dyes. See “Semiconductor Beacons Light up Cell Structures” ⁇ Service, Science, Vol. 281.
  • the conventional fluorescent dye typically made from small organic dye molecules can be toxic, can quench quickly, and can be difficult to use in tandem, since typically each dye must be excited with photons at a different wavelength.
  • the quantum dots compared with conventional coloring agents such as rhodamine 6G or other organic dyes, the quantum dots produce narrower and much brighter fluorescence spectra. See “Quantum Dots Meet Biomolecules", Jacoby.
  • the absorbency onset and emission maxima shift to a higher energy with decreasing size.
  • the excitation typically tracks the absorbency, resulting in a tunable fluorophore that can be excited efficiently at any wavelength shorter than the emission peak, yet will emit with the same characteristic a narrow, symmetric spectrum regardless of the excitation wavelength. See “Semiconductor Nanocrystals as Fluorescent Biological Labels", Bruchez, et al., Science. Vol. 281, 1998.
  • the color can be changed. Additionally, a range of quantum dots of different colors may be excited with a single wavelength and detected simultaneously. See “Bright Lights for Biomolecules", Analytical Chemistry News and Features,
  • quantum dots or semiconducting nanocrystals, are much more flexible and advantageous when used in assays.
  • the attachment of biologically active ligands to nanocrystals including, for example, cadmium selenide nanocrystals is a new method of producing novel fluorescent sensors.
  • the sensors can have a variety of applications. They may be used in fundamental studies ranging from assay systems to locate the distribution and localization of membrane bound receptors, transporter proteins and channels in whole assay systems. They may also be used in novel methodologies for the development of pharmaceutically active compounds using high throughput screening.
  • the small size of the of the nanocrystal ligand conjugate offers advantages over conventional techniques that use antibodies bound to fluorescent dyes. These advantages include the small size of the drug nanocrystal conjugate, which enables it to fit into the synaptic gap. Antibody-fluorescent dye systems are much larger than the nanocrystal drug conjugates of the present invention, so the antibody-fluorescent dye stems are less likely to fit into the synaptic gap. Additionally most antibodies are cell permeable. The increased photostability of the nanocrystals means that they are not as easily photo -bleached as conventional dyes. Therefore, the nanocrystal compounds of the present invention may be used in experiments that require longer periods of illumination without photo-bleaching becoming a major problem.
  • the increased brightness of the nanocrystals enhances the sensitivity of the assay systems when compared to traditional dyes. Therefore, assay systems can be developed that detect lower concentrations of the analyte.
  • U.S. Patent No. 5,990,479 to Weiss et al. discloses a luminescent nanocrystal compound that is capable of linking to an affinity molecule. Weiss et al. further describe a process for making luminescent semiconductor nanocrystal compounds and for making an organo luminescent semiconductor probe comprising the nanocrystal compound linked to an affinity molecule capable of bonding to a detectable substance and a process for using the probe to determine the presence of a detectable substance in a material.
  • U.S. Patent No. 5,751,018 to Alivisatos et al. discloses methods for attaching semiconductor nanocrystals to solid inorganic surfaces, using self-assembled bifunctional organic monolayers as bridge compounds.
  • U.S. Patent No. 5,537,000 to Alivisatos et al. which describes electroluminescent devices formed using semiconductor nanocrystals as an electron transport media and a method for making such electroluminescent devices.
  • U.S. Patent No. 5,505,928 to Alivisatos et al. discloses nanocrystals of I1I-V semiconductors
  • U.S. Patent No. 5,262,352 Alivisatos et al. discloses a process for forming a solid, continuous thin film of a semiconductor material on a solid support surface.
  • An embodiment of the present invention is to provide linker arms to attach organic compounds to nanocrystals, or quantum dots.
  • a linker arm of the present invention may have the following formula:
  • Z O, CH2, or NH
  • Y represents the attachment point to the nanocrystal and X represents the attachment point of an organic compound.
  • R is a bond or is selected from the group consisting of:
  • n 1-10, with S being attached to the nanocrystal.
  • R 2 is a bond or selected from the group consisting of carbonyl, NH, S, CONH, COO, S, C ⁇ - ⁇ o alkyl, carbamate, and thiocarbamate .
  • n and p are 1 or more, the resulting carbon or carbon chain may be substituted.
  • z is CH 2 .
  • n and p are 1-5.
  • the linker arm may have the following formula:
  • R 2 is a bond or selected from the group consisting of carbonyl, O, NH, S,
  • Ci-io alkyl carbamate, and thiocarbamate .
  • R 3 is selected from the group consisting of: SH, O(CH 2 (n)O)nSH,
  • n 1-10. S is attached to the nanocrystal.
  • the organic compound is a biologically active compound.
  • biologically active compounds of the present invention include seratonin or seratonin derivatives, cocaine analogues, phenyl tropane analogues, phenylisopropylamine derivatives, dopamine derivatives, melatonin derivatives, chlormethiazole derivatives, derivatives of RTI-4229-75, and derivatives of GBR 12935. RTI-4229-75 and GBR 12935 are further described below.
  • the preferred organic compounds attached to the nanocrystal of the present invention specifically include the following:
  • R represents the attachment point to the linker arm. Additionally, the R group may be "floating" when attached to the phenyl ring. That is, the R group may be attached to any available carbon atom on the ring.
  • the present invention further is directed to nanocrystal compounds, which include linker arm derivatives of the present invention. More specifically, the nanocrystal compounds of the present invention comprise a semiconducting nanocrystal and a hnking arm having a first portion hnked to the nanocrystal and a second portion linked to an organic compound. Examples of nanocrystal compounds of the present invention include the following formulae (II), (III), (IV), (V), (VI), (VII), (X) and (XI):
  • n 0-10
  • n 2,3,4 or 5.
  • the linker arm may be attached to positions 1,2,3, or 4. Most preferably, the linker arm is attached to position 2.
  • n is 1, 2, 3, or 4 and the linker arm is attached to positions 1, 2, 3, or 4. Most preferably, positions 1, 2, or 3. Most preferably, position 2.
  • n 1, 2, 3, 4 or 5 and the linker arm is attached to positions 1, 2, 3, or 4.
  • the linker arm is attached to one of positions 1, 2, or 3.
  • X H or halogen.
  • X is H or F.
  • n 0-10
  • n 2-10
  • the linker arm may be attached to positions 1, 2, 3, or 4.
  • position 2 Preferably, position 2.
  • n 0-10
  • n is 2, 3, 4, or 5.
  • the linker arm may be attached to positions 1 or 2. Preferably, position 2.
  • n 0-10
  • n is 2, 3, 4 or 5.
  • the linker arm may be attached to positions 1,2, 3, or 4. Preferably, position 2.
  • n 0-10
  • n is 2, 3, 4 or 5.
  • the linker arm may be attached to positions 1, 2, 3, or 4. Preferably, position 2.
  • n 0-10
  • n is 2,3,4 or 5.
  • the linker arm may be attached itions 1,2, 3, or 4.
  • position 2 Preferably, position 2.
  • n 0-10
  • n is 2, 3, 4 or 5.
  • the linker arm may be attached to positions 1, 2, 3, or 4. Preferably, position 2.
  • n 0-10
  • n is 2,3,4 or 5.
  • the hnker arm may be attached to positions 1, 2, 3, or 4. Preferably, position 2.
  • n is 2,3,4 or 5.
  • the linker arm may be attached to positions 1 or 2. Preferably, position 2.
  • the linker arm attaching the compounds to the nanocrystal can be altered by attaching a polyethylene glycol to it. Additionally, the linker arm may be altered by replacing a carbon with an oxygen, sulfur, or NH group. The length of the linker arm may be increased or decreased and it may comprise chains with lengths of, for example, 1 to 10 carbons.
  • the present invention relates to linker arms to which biologically active molecules can be attached to nanocrystals.
  • the nanocrystals used in conjunction with the present invention are the nanocrystals typically used in fluorescent imaging techniques.
  • the nanocrystals used in conjunction with the present invention are semiconductor nanocrystals capable of luminescence and/ or scattering or diffraction when excited by an electromagnetic radiation source (of broad or narrow bandwidth) or a particle beam, and capable of exhibiting a detectable change of absorption and/ or emitting radiation in a narrow wavelength band and /or scattering or diffracting when excited.
  • the nanocrystals of US 5,990,479 may be used with the present invention.
  • an organic or inorganic single crystal particle having an average cross-section of about 20 nanometers (nm) or 20 x 10 9 meters (200 Angstroms), preferably no larger than about lOnm (100 Angstroms) and a minimum average cross-section of about lnm, although in some instances a smaller average cross- section nanocrystal, i.e., down to about 0.5nm (5 Angstroms), may be acceptable.
  • the nanocrystal will have an average cross-section ranging in size from about 1 nm (10 Angstroms) to about 10 nm (100 Angstroms).
  • these nanocrystals include, but not are limited to CdSe, CdS, PbSe, PbS, and CdTe.
  • the nanocrystal compounds of the present invention can overcome the above deficiencies.
  • the nanocrystal compounds comprise core (CdSe)/shell(ZnS) semiconducting nanocrystals. Through quantum confinement, the fluorescent wavelength of these nanocrystals are continuously tunable by size.
  • a 25 Angstrom nanocrystal of this embodiment emits at 455nm while a 60 Angstrom nanocrystal of this embodiment emits at 625 nm.
  • these nanocrystals have narrow gaussian emission spectra enabling multiplex imaging.
  • the absorption of these nanocrystals is continuous above the band-gap; hence all sizes of nanocrystals can be excited with a single excitation wavelength.
  • the nanocrystals of this embodiment are much brighter than traditional dyes, even hours after continuous illumination.
  • the present invention further relates to multiple organic compounds in combination with the linker arms of the present invention.
  • the present invention further relates to a method of attaching a hnker arm to multiple organic compounds and a method of attaching a linker arm to a nanocrystal.
  • the present invention further relates to the linker arms herein described and nanocrystals attached to the linker arms herein described.
  • the present invention also relates to nanocrystals and semiconductor nanocrystals in combination with the linker arms of the present invention.
  • the present invention further relates to the attachment of a nanocrystal and a linker arm to an organic compound.
  • the present invention relates to assay systems and assay kits for CNS research, receptor purification, pathogens, environmental contaminants, toxins, and screening for drugs, insecticides, herbicides, and other biologically active substances.
  • the linker arms and linker arm compound derivatives of the present invention enhance stability and are relatively stable, including stability to biological degradation.
  • the linker arms and the linker arm compound derivatives of the present invention are also advantageous in that they can be synthesized at a relatively low cost.
  • the present invention relates to linker arms such as, for example, carbon-carbon chain hnker arms by which biologically active molecules such as CNS drugs and neurotransmitters can be attached to nanocrystals.
  • the attachment of a linker arm of the present invention allows nanocrystals to be used as imaging agents in diverse applications such as biochemical research, CNS research, receptor purification, and high throughput screening for new drugs and other biologically active substances.
  • the present invention relates to hnker arms such as, for example, carbon hnker arms by which biologically active molecules such as drugs, hormones, etc. can be attached to nanocrystals.
  • the linker arms of the present invention enhance water solubility of nanocrystals and allow nanocrystals to be attached to a diverse range of molecules ranging from drugs to polypeptides and neurotransmitters.
  • the linker arm compounds of the present invention allow nanocrystals to be used as imaging agents in diverse applications such as CNS research, receptor purification, assay systems for pathogens, environmental contaminants, toxins, and a high throughput assay system for new drugs and biologically active molecules.
  • the organic part of the nanocrystal compounds of the present invention are biologically active compounds.
  • the biologically active compound is one that will bind to detectable substances, if the substance is present, in the material being analyzed.
  • affinity molecules useful in the prior art in combination with a dye molecule to provide specific recognition of a detectable substance will find utility in the formation of the organo-luminescent semi conductor nanocrystal probes of the invention.
  • affinity molecules include, by way of example only, such classes of substances as monoclonal and polyclonal antibodies, nucleic acids (both monomeric and oligomeric), proteins, polysaccharides, and small molecules such as sugars, peptides, drugs, and ligands. Lists of such affinity molecules are available in the published literature such as, by way of example, the "Handbook of Fluorescent Probes and Research Chemicals", (sixth edition) by R.P Haugland, available from Molecular Probes, Inc.
  • the compounds of the present invention enable nanocrystals to be used as probes for neurotransmitters, receptors and transporter proteins.
  • seratonin (5-hydroxytriptamine) is attached to a nanocrystal.
  • Seratonin is a neurotransmitter which has been linked to the regulation of critical behaviors including sleep, appetite, and mood.
  • the seratonin transporter (SERT) is a 12 -transmembrane domain protein responsible for the uptake of seratonin by the cell.
  • the seratonin labeled nanocrystal compounds of the present invention have a measurable ability to block the uptake of tritiated sepatonin by the human and Drosophila seratonin transporter (hSERT and dSERT).
  • Seratonin labeled nanocrystals may be prepared by reacting trioctylphosphineoxide coated nanocrystals with seratonin and tetramethylammonium hydroxide in methanol.
  • the SNACs are isolated by precipitation and purified to remove seratonin. Linkage of the seratonin presumptively occurs through the lone pair of the hydroxyl to the Cd surface atoms of the nanocrystal.
  • hSERT and dSERT are transfected into HeLa cells via a vaccinia virus/T7 expression system.
  • Ki values the concentration at which half the SNACs are bound to the transporter, are determined by nonlinear regression.
  • Ki the concentration at which half the SNACs are bound to the transporter.
  • nanocrystals can be used as probes for SERT. These probes assist in determining the structure of SERT, including the number of gene products (SERT proteins) that are required to assemble a functional unit, and following transporter movement within the cell.
  • the present invention enables nanocrystals to be used as imaging agents, which results in an assay system that is superior to traditional immunoassay systems because, among other things, several wavelengths can be used to induce fluorescence.
  • the linker arm can be attached to a number of different ligands, thus enabling them to be used in high throughput screening and receptor purification.
  • the hnker arm is stable and not as subject to enzymatic degradation as other hnker arms may experience.
  • the linker arm of the present invention also enhances the solubility of the nanocrystal, and can be readily derivitised. This enables a wide range of molecules to be attached to the nanocrystals.
  • the linker arm of the present invention is not as temperature sensitive as many immunoassay systems, and thus is likely to have a longer shelf life. Further, the linker arm of the present invention is also robust and therefore not susceptible to extremes of pH that may denature and degrade peptide linkers.
  • the linker arm of the present invention may have the following formula:
  • Z O, CH2, or NH
  • R is a bond or is selected from the group consisting of SH, O(CH 2( n)O) n SH, NH(CH (n)O) n SH, NH(CH 2( n)NH)SH, S(CH 2 (n)O) n SH, and S(CH 2 (n)S)SH.
  • n is 1-10, with S being attached to the nanocrystal.
  • R2 is a bond or selected from the group consisting of carbonyl, NH, S, CONH, COO, S, C ⁇ -10 alkyl, carbamate, and thiocarbamate .
  • n and p are 1 or more, the resulting carbon or carbon chain may be substituted.
  • z is CH2.
  • n and p are 1-5.
  • the hnker arm of the present invention may have the following formula:
  • Y is an attachment point for a nanocrystal
  • X is an attachment point of an organic compound
  • R2 is a bond or a group selected from the group consisting of: carbonyl, NH, O, S, CONH,
  • Ci-io alkyl carbamate, and thiocarbamate .
  • R 3 is: SH
  • n 1-10, with S being attached to the nanocrystal.
  • n 1 to 5.
  • the length of the linker arms of the present invention may be increased or shortened in order to increase the solubility of the nanocrystal drug conjugate and increase the affinity of the ligand for its target protein.
  • the hnker arms of the present invention include the following compounds:
  • R represents the point of attachment of an organic compound.
  • the nanocrystal compounds of the present invention include the following, with S being attached to the nanocrystal:
  • Nanocrystal compounds of the present invention include compounds that comprise of nanocrystals with the following specific and preferred features: a CdSe core, ZnS shell, generally their cores are less than 25nm, in diameter.
  • the surrounding ZnS shell is typicaUy 10 to 20nm in thickness, and the ligand coated core shells are water solubilised by the addition of a mercapto acetic acid co- solubility ligand.
  • an embodiment of the present invention is an assay kit developed for the detection of a diverse range of substances ranging from environmental contaminant such as DDT, dioxanes, chemical warfare agents, herbicides, pesticides, and pathogenic organisms such as Ecoli 0157 and Salmonela.
  • the present invention comprises a process for treating a material, such as a biological material, to determine the presence of a detectable substance in the material.
  • the process comprises contacting the material with a nanocrystal conjugated compound of the present invention, washing unbound nanocrystal conjugated compound away, and exposing the material to energy such as an electromagnetic source or particle beam capable of exciting the nanocrystal conjugated compound of the present invention, and causing a detectable fluorescence to occur in the nanocrystal conjugated compound of the present invention.
  • energy such as an electromagnetic source or particle beam capable of exciting the nanocrystal conjugated compound of the present invention
  • the nanocrystal compounds of the present invention may be used in the assays described in US Patent 5,990,479.
  • One assay system of the present invention is a high throughput fluorescence assay to identify novel ligands that might be effective antidepressants or ligands that might help combat cocaine addiction.
  • a known agonist or antagonist for the dopamine receptor or transporter is bound to nanocrystals, and incubated with cells that either naturally express or have been engineered to express dopamine receptors or transporters. After incubating for 12 hours excess ligands are removed by washing and unknown compounds are incubated with the cells for a further 12 hours. The cells are washed again with buffer and a fluorescence assay is performed. Any cells that no longer fluoresce have a high affinity ligand bound to them and this ligand may be used as a lead compound for drug discovery.
  • Such an assay system may be carried out in a conventional multiple well format system, such as the 96 well format.
  • Chart A below demonstrates another method of the present invention that may be used to detect biologically active analytes.
  • Chart A describes a sandwich assay system.
  • step 1 monoclonal or polyclonal antibodies raised against a specific analyte or groups of analytes are bound to the surface of the plate.
  • step 2 the analyte is added and binds to the antibody.
  • step 3 the unbound analyte is washed away and a nanocrystal antibody conjugated using our linker arm of the present invention is added (once again poly or monoclonal antibodies may be used).
  • step 3 the unbound nanocrystal antibody conjugates are removed by washing, and a fluorescence assay is performed to determine if the analyte is present in the sample being analyzed and its concentration as a sample with a higher concentration will produce a greater fluorescence.
  • Multiple analytes can be screened for using a conventional 96 well plate format.
  • Monoclonal or polyclonal antibodies raised against a specific analyte or group of analytes are bound to a surface.
  • NC nanocrystal. A sandwich assay system.
  • the nanocrystal of the present invention may be used in affinity chromatography, where a compound or biological molecule of interest may be bound to a column. This may then be specifically labeled with the antibody nanocrystal conjugate, substrate nanocrystal conjugate, or drug nanocrystal conjugate of the present invention.
  • the compound could be a drug, a hormone, an enzyme, a protein, a nucleic acid or a receptor.
  • the nanocrystal conjugate Once the nanocrystal conjugate has bound to the substrate of interest, it may either remain bound to the column or be eluted with the mobile phase. This would enable the isolation and identification of the compound or biological molecule of interest. Unlike fluorescent dyes, nanocrystals are not easily photo- bleached.
  • Such a system may be apphed to several different analytes enabling the identification of several unknowns at once by using different sized nanocrystals conjugated to different ligands.
  • receptor classes or subtypes e.g. 5-HT receptor subtypes
  • the linker arm acts as a spacer and separates the ligand from the nanocrystal thus possible steric and other interactions between nanocrystals and ligand are minimized.
  • the hnker arm may be an ethylene glycol moiety this helps to enhance the solubihty in aqueous media. Many affinity chromatographic systems are typically run in such media.
  • the polyether hnker arm is also resistant to proteolytic cleavage which may be a problem with other assay systems.
  • Nanocrystals can be attached to enzymes via linker arms of the present invention.
  • the amino derived carboxylic acid derived poly ethers may be linked to the backbone of the peptide via a peptide bond.
  • the linker arm removes the enzyme from the immediate environment of the nanocrystal. This may be important in reducing any effects that the nanocrystal may have upon the enzymes activity. Many such instances could be envisaged particularly if the enzyme or protein undergoes a conformational change during its catalytic cycle (e.g.
  • the linker arm may increase the catalytic efficiency of the enzyme if the active site or sites are close to the enzymes surface.
  • Such a system may also be used to identify analytes in a similar manner to the nanocrystal antibody conjugates previously described. It may also be used in high throughput screening where the compounds of interest are bound to wells in plates and the enzyme nanocrystal conjugate is added. An example of this is shown in chart B below.
  • Chart B identifying active compounds in a high throughput assay system
  • the enzymes substrate or inhibitor may also be bound to the polyethylene glycol nanocrystal conjugate.
  • the linker arm of the present invention reduces steric hindrance between nanocrystal and enzyme and it enables the substrate to enter the enzymes catalytic or alosteric site, which may not be possible if the substrate were bound to the surface of the nanocrystal (particularly if the site of interest is deep within the enzyme).
  • An assay system that could use this technique as a tool for identifying new drugs is outlined in chart C, below, where compounds that will compete for the site of interest can be identified. If the nanocrystal is bound to an inhibitor via the linker arm of the present invention it is likely that this assay system could also be used to identify other inhibitors of the enzyme.
  • F,J,X and Z are new chemical entities bound to nanocrystals via our linker arm.
  • Inactive compounds will not bind and will be washed away thus we have an assay system for detecting novel active compounds.
  • One specific substance may also be bound to the nanocrystal (e.g. a substrate for the enzyme) and a simple competitive assay could be performed with unknown substances in a manner similar to that shown above in chart C.
  • Any substance that has a higher affinity for the site of interest on the enzyme, protein or receptor than the ligand conjugated nanocrystal would displace the ligand conjugated nanocrystal resulting in a loss off fluorescence, thus enabling this system also to be used as a high throughput assay system as well as an analytical tool for environmental contaminants, toxins, and other unknowns.
  • This system can be applied to receptors rather than enzymes.
  • the nanocrystal is bound to an agonist, antagonist, or natural ligand for the receptor (e.g. Seratonin).
  • This system could be used as an assay system for receptor agonist or antagonist. It would be of interest in neuropharmacology where receptor location and distribution could be mapped.
  • By attaching different sized nanocrystals to different agonists, antagonists, or ligands it may be feasible to develop multiplexing assay systems, thus enabling the effects of drugs and other neurologically active agents to be monitored in whole cell assay systems.
  • Nanocrystals may be attached to DNA or RNA via the hnker arm of the present invention.
  • the major role of the hnker arm acts as a spacer and reduces steric hindrance.
  • the DNA or RNA conjugates may be used as a tool in molecular biology for identifying the location and frequency and rate of expression of specific gene sequences. Such a system is outlined in chart D, below.
  • a nanocrystal via the linker arm Then wash.
  • the sections of the DNA or RNA of interest will bind to our probe.
  • the nanocrystal conjugates of the present invention can also be used in assay systems in the same manner that antibody fluorescent dye conjugates, radio immuno assays, and ELISA are used.
  • Examples of the assay system include routine assays used in medical laboratories such as tests for various disease states, for example HIV, Diabetes, etc.
  • Example 1 A nanocrystal conjugated biologically active compound of the present invention may be made as follows:
  • a hnker arm for the above compound may be made as
  • X SH or O(CH 2 CH 2 ) m
  • N-Carbethoxyphthalimide (i) NBS, PPI13; (iii) Potassium thioacetate,
  • Adipoyl chloride (50ml) and aluminum chloride (lOg, 7.4 mmols) are dissolved in nitrobenzene (50ml) and cooled to 0°C, in a three necked 250ml round bottomed flask equipped with a stirrer, thermometer, addition funnel and a calcium chloride drying tube.
  • 1,4-Dimethoxybenzene (lOg, 7.2 mmols) in nitrobenzene (50ml) is added drop wise over a 3 hour period and the temperature is maintained below 5°C. The resulting mixture is stirred for a further 2 hours at 0 C.
  • 6-(2,5-dimethoxy-phenyl)-6-oxohexanoic acid (4.2g, 160 mmols) is added to methanol (100ml) in a 250ml round bottomed flask equipped with a stirrer and a reflux condenser. A catalytic quantity of concentrated sulfuric acid (2 drops) is added. The solution is heated at reflux over a period of 18 hours with stirring. After cooling to room temperature the solution is evaporated under reduced pressure and the crude product is dissolved in diethyl ether (100ml). This is washed with sodium carbonate (saturated, 50ml) and water (50ml). It is dried over magnesium sulfate filtered and evaporated under reduced pressure. The product is purified using column chromatography on silica gel eluted with dichloromethane. This gives approximately 4.2g (94%) of the product as a pale yellow oil.
  • Powdered zinc (22.5g) is added to a solution of mercuric chloride (0.94g) in concentrated hydrochloric acid (0.93ml) and water (23.1ml). This suspension is shaken for 5 minutes and the liquid is decanted.
  • the amalgamated zinc is placed in a 500ml 3 necked flask and concentrated hydrochloric acid (12ml) is added. The flask is heated to cause a gentle reflux and a solution of Methyl- 6- (2,5- dimethoxyphenyl) -6-oxohexanoate (4.2g, 15 mmols) in methanol (7ml) and concentrated hydrochloric acid (23ml) is added drop wise.
  • a mixture of phosphorus oxychloride (1ml) and N- methylformanilide (1.81g) are allowed to incubate at room temperature for 30 minutes, in a 25ml round bottomed flask equipped with a stirrer and a reflux condenser.
  • Methyl-6-(2,5-Dimethoxyphenyl)hexanoate (lg, 4 mmols) is added and the mixture is heated for 2 hours. After cooling to room temperature water (50ml) is added and the mixture is left standing at room temperature for 18 hours. Then the solution is extracted with dichloromethane (2X100ml) dried over magnesium sulphate filtered and evaporated.
  • the inorganic salts are air died and washed with dichloromethane (2X 100ml) and the aqueous solution is extracted with (2X100ml). The combined organic extracts are dried over magnesium sulfate filtered and evaporated to yield approximately 0.25g (66%) of the product as a colorless sohd.
  • 6-(2,5-Dimethoxy-4-(2-[N,N-phtahmido]propyl)phenyl)hexanol (0.2g,0.4 mmols) is dissolved in dichloromethane (20ml) and cooled to 0°C in a 50ml round bottomed flask equipped with a thermometer, dropping funnel and a stirrer.
  • Triphenyl phosphine (0.13g, 0.51 mmols) in dichloromethane (10ml) is added drop wise to the solution of (40). After stirring for 30 minutes a solution containing N- bromosuccinamide (0.09g, 0.5 mmols) in dichloromethane (10ml) is added drop wise over 10 minutes.
  • 6-(2,5-Dimethoxy)-4-(2-[N,N- phtalimido]propyl)pheny ⁇ )hexylbromide (0.28g, 0.57 mmols) is dissolved in dry dimethyl formamide (10ml), in a 25ml round bottomed flask equipped with a stirrer and 4 A molecular sieves (10 pellets) are added. The solution is stirred for 1 hour at room temperature, before the addition of potassium thioacetate (0.13g, 0.00114mols). Stirring is continued at room temperature for a further 18 hours. After which it is filtered and diethyl ether (100ml) is added to the solution.
  • 6-(2,5-Dimethoxy-4-(2-[N,N- phtalimido]propyl)phenyl)hexylthioacetate (0.23g, 0.47 mmols) is dissolved in absolute ethanol (50ml) in a 500ml round bottomed flask equipped with a stirrer. Hydrazine monohydrate (15ml) is added to this solution and the mixture is stirred at 22°C for 90 minutes. Dichloromethane (200ml) is added and the solution is washed with water (2 x 100ml). The organic solution is dried over magnesium sulphate filtered and evaporated. This gives approximately O. lg (68%) of the product as a pale yellow oil.
  • 6-(2,5-Dimethoxy-4-(2-[N-(tert- butoxycarbonyl)aminopropyl] phenyl) hexyl thiol (0.04 lg, 0.097 mmols) is dissolved in dry toluene (10ml) in a 25ml round bottomed flask equipped with a stirrer. Trifluoroacetic acid (0.2ml) is added the mixture is stirred at 22°C for 1 hour. The solvent is removed under reduced pressure and the resultant tar is dissolved in dichloromethane (20ml). This is washed with sodium bicarbonate (0.1M, lx 20ml) and water (2 x 10ml). After drying over magnesium sulfate the solution is filtered and evaporated. This gives approximately 0.02 lg (70%) of the product as a pale yellow oil.
  • 6-(2,5-Dimethoxy-4-(2-[N-(tert- butoxycarbonyl)aminopropyl] phenyl) hexanol (0.018g, 0.045 mmols) is dissolved in dichloromethane (20ml) and cooled to 0°C in a 50ml round bottomed flask equipped with a stirrer.
  • Triphenyl phosphine (0.13g, 0.049 mmols) in dichloromethane (10ml) is added drop wise followed by N-bromosuccinamide (0.09g, 0.05 mmols) in dichloromethane (10ml).
  • 6-(2,5-Dimethoxy-4-(2-[N-(tert-butoxycarbonyl)aminopropyl] phenyl) hexylbromide (0.07g, 0.015 mmols) is dissolved in dry dimethylformamide (2ml) in a 25ml round bottomed flask equipped with a stirrer, 4 A molecular sieves (6 pellets) are added and the mixture is stirred at 22°C for 1 hour. After which potassium thioacetate (0.035g, 0.03 mmols) is added. The solution is stirred for 18 hours at 22°C, filtered and diethyl ether (50ml) is added .
  • 6-(2,5-Dimethoxy-4-(2-[N-(tert-butoxycarbonyl)aminopropyl] phenyljhexylthioacetamide (0.051g, 0.011 mmols) is dissolved in methanol (5ml) in a 10ml round bottomed flask equipped with a stirrer. Methanohc ammonia (25ml) is added and the mixture is stirred at 22°C for 3 hours and evaporated.
  • 11-Bromoundecanoyl chloride is synthesised as described by Goodman et. al. In the Journal of medicinal chemistry ⁇ 390, 1984.
  • a solution of 11-bromoundecanoic acid (10.6g, 0.04 mols) and thionyl chloride (4ml, 0.07 mols) in DMF (0.5ml) is stirred at 80°C for 1 hour. The solution is cooled to room temperature and used in the next step without purification.
  • the etherial solution is dried over magnesium sulfate, filtered and evaporated.
  • the product is purified by dry flash chromatography on silica eluted with ethylacetate/ hexanes 50:50, followed by recrystalisation from petroleum spirit. This gives approximately 8g (50%) as a colorless solid.
  • the etherial layer is removed and the aqueous solution is washed with diethyl ether (2 x 100ml).
  • the acidic solution is neutralised with base and the salts are removed by filtration.
  • the solids are extracted with dichloromethane (2 x 100ml) and the aqueous solution is extracted with dichloromethane (2 x 100ml).
  • the combined organic extracts are dried over magnesium sulfate filtered and evaporated. This yield approximately 0.4g (35%) of the product as a brown oil.
  • the linker arm of the present invention may be derivatized and further lengthened by adding a polyethylene glycol an illustrative example is outlined in chart 5.
  • n 0 to 10
  • p 0 to 10 and X is I, Br, or Cl.
  • n l, 2 and 3
  • p 2,3,4,5,6,7,8,and 9.
  • Example 3 Further example of preparing a nanocrystal conjugated biologically active compound of the present invention.
  • linker arm used in the ligand (II), above, is made as
  • n 1,2,3,4,5,6,7,8,9, 10, l l,and 12.
  • X is F or H.
  • 11-bromoundecanoic acid (0.42g, 0.0016 mols) is dissolved in dry dichloromethane (50ml) and thionyl chloride (1ml) is added. A catalytic quantity of dry dimethyl formamide (1 drop) is added and the mixture is heated at reflux for 30 minutes. The solvent is removed under reduced pressure and the acid chloride is dissolved in dry dichloromethane (20ml) This solution is added dropwise to a methylene chloride solution containing l-[2-[bisphenylmethoxy]ethyl]-4-(3-(4- aminophenyl) propyl) piperazine (0.64g ,0.00 mols) and triethylamine (lml).
  • Example 4 This example demonstrated how the linker arm of the present invention may be derivatized and lengthened.
  • the linker arm of the present invention may be derivatized and further lengthened by adding a polyethylene glycol an illustrative example is outlined in chart 7.
  • the biologically active molecule is attached to the linker arm via a functional group or a methylene group.
  • R may be O, NH, S, CH 2 , etc.
  • PG is a protecting group and may be para-methoxy benzyl, benzyl, a thioamide, a thio ether, etc.
  • This example discloses a method of attaching linker arms of the present invention to nanocrystal core shells.
  • An example of the methodology used is outlined below:
  • trioctylphosphine oxide coated core shells 9 mg are weighed out and suspended in pyridine (2ml). The concentration and thus the number of moles of nanocrystals may be determined before hand using
  • the water solubility of the ligand functionalised core shells may be increased if necessary by using a modification of the method of Fred Mikulec (private communication).
  • Mercaptoacetic acid (1ml) and dimethyl formamide (1ml) are added to the ligand coated core shells and stirred at room temperature under argon for 2 hours. After cooling to room temperature the solution is diluted with dimethyl formamide (100ml) and potassium teriary butoxide (1.61g) is added. The resulting solid is collected by centrifugation and is washed with tetrahydrofuran (4 x 100ml) and methanol (7 x 100ml).
  • the product is collected by centrifugation to yield 45 mg of l-[2-bisphenylmethoxy]ethyl]-4-(3-(4-(3,6-dioxa-8- thiol)octanamidophenyl) propyl piperazine (25) coated nanocrystals. After drying the precipitate under reduced pressure for 4 days at room temperature the ligand coated cores can be dissolved in a minimum quantity of buffer in a pH range of 6 to 8.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne, de façon générale, des composés nanocristallins, ainsi que des bras de liaison pour composés nanocristallins permettant de rattacher les nanocristaux aux composés organiques. Le composé nanocristallin comprend un nanocristal, un bras de liaison et un composé organique. De préférence, le composés organique est un composé biologiquement actif pouvant servir de sonde fluorescente. De préférence, l'arbre de liaison est une chaîne carbonée pourvue d'un point d'attache pour le nanocristal et d'un point d'attache pour le composé organique. Plus précisément, le nanocristal est rattaché au bras de liaison par l'intermédiaire d'un groupe R3 et le composé organique est rattaché au bras de liaison par l'intermédiaire d'un groupe R2. Le groupe R2 est une liaison ou il est sélectionné dans le groupe constitué de carbonyle, O, NH, S, CONH, COO, S, C1-10 alkyle, carbamate et thiocarbamate. Le groupe R3 est sélectionné dans le groupe constitué de : SH, O(CH2(n)O)nSH, NH(CH2(n)O)nSH, NH(CH2(n)NH)SH, S(CH2(n)O)nSH, S(CH2(n)S)SH, et d'une chaîne polymère. n est compris entre 1 et 10. S est attaché au nanocristal.
PCT/US2001/016947 2000-05-24 2001-05-24 Bras de liaison pour nanocristaux et composes correspondants WO2001090717A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001266609A AU2001266609A1 (en) 2000-05-24 2001-05-24 Linker arms for nanocrystals and compounds thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20677100P 2000-05-24 2000-05-24
US60/206,771 2000-05-24

Publications (2)

Publication Number Publication Date
WO2001090717A2 true WO2001090717A2 (fr) 2001-11-29
WO2001090717A3 WO2001090717A3 (fr) 2002-04-04

Family

ID=22767882

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/016947 WO2001090717A2 (fr) 2000-05-24 2001-05-24 Bras de liaison pour nanocristaux et composes correspondants
PCT/US2001/016739 WO2001090716A2 (fr) 2000-05-24 2001-05-24 Bras de liaison pour nanocristaux et composes de ces derniers

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016739 WO2001090716A2 (fr) 2000-05-24 2001-05-24 Bras de liaison pour nanocristaux et composes de ces derniers

Country Status (2)

Country Link
AU (2) AU2001264875A1 (fr)
WO (2) WO2001090717A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110394167A (zh) * 2019-07-22 2019-11-01 中国科学院兰州化学物理研究所 四乙烯五胺碳量子点/单体共键合硅胶亲水色谱固定相的制备及应用
US11078144B2 (en) 2019-10-24 2021-08-03 Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C Process for synthesizing of hydroquinone derivatives with heptadecatrienyl side chain

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208605A (zh) * 2005-05-04 2008-06-25 新加坡科技研究局 含有低分子量涂布剂的新型水溶性纳米晶及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5751018A (en) * 1991-11-22 1998-05-12 The Regents Of The University Of California Semiconductor nanocrystals covalently bound to solid inorganic surfaces using self-assembled monolayers
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
WO2000027365A1 (fr) * 1998-11-10 2000-05-18 Biocrystal Limited Nanocristaux fonctionnalises et leur utilisation dans des systemes de detection
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6221602B1 (en) * 1998-11-10 2001-04-24 Bio-Pixels Ltd. Functionalized nanocrystals and their use in labeling for strand synthesis or sequence determination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188340A (en) * 1969-08-01 1980-02-12 The Dow Chemical Company Polyethers having aminothioether side chains
US3873680A (en) * 1972-08-30 1975-03-25 Minnesota Mining & Mfg Mercaptan and thioketal complexes of technetium 99M for diagnostic scanning
US3892878A (en) * 1973-04-25 1975-07-01 Int Flavors & Fragrances Inc Flavoring with sulfur containing compounds
JPS58183666A (ja) * 1982-04-20 1983-10-26 Nippon Tokushu Noyaku Seizo Kk 置換フエノキシプロピオン酸エステル、その製造中間体、該エステル及び該中間体の製法、並びに除草剤
US4720585A (en) * 1985-09-18 1988-01-19 E. R. Squibb & Sons, Inc. Aminopeptidase inhibitors
US5075511A (en) * 1986-10-30 1991-12-24 Shell Oil Company Process and alkylmercaptoamine catalyst for production of bisphenol-A
US5912319A (en) * 1997-02-19 1999-06-15 Courtaulds Aerospace, Inc. Compositions and method for producing fuel resistant liquid polythioether polymers with good low temperature flexibility

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5751018A (en) * 1991-11-22 1998-05-12 The Regents Of The University Of California Semiconductor nanocrystals covalently bound to solid inorganic surfaces using self-assembled monolayers
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
WO2000027365A1 (fr) * 1998-11-10 2000-05-18 Biocrystal Limited Nanocristaux fonctionnalises et leur utilisation dans des systemes de detection
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6221602B1 (en) * 1998-11-10 2001-04-24 Bio-Pixels Ltd. Functionalized nanocrystals and their use in labeling for strand synthesis or sequence determination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAN W.C.W. ET AL.: 'Quantum dot bioconjugates for ultrasensitive nonisotopic detection' SCIENCE vol. 281, 1998, pages 2016 - 2018, XP002905480 *
SERVICE R.F.: 'Semiconductor beacons light up cell structures' SCIENCE vol. 281, 1998, pages 1930 - 1931, XP002905481 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110394167A (zh) * 2019-07-22 2019-11-01 中国科学院兰州化学物理研究所 四乙烯五胺碳量子点/单体共键合硅胶亲水色谱固定相的制备及应用
CN110394167B (zh) * 2019-07-22 2021-10-08 中国科学院兰州化学物理研究所 四乙烯五胺碳量子点/单体共键合硅胶亲水色谱固定相的制备及应用
US11078144B2 (en) 2019-10-24 2021-08-03 Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C Process for synthesizing of hydroquinone derivatives with heptadecatrienyl side chain

Also Published As

Publication number Publication date
WO2001090716A3 (fr) 2002-04-04
WO2001090717A3 (fr) 2002-04-04
AU2001264875A1 (en) 2001-12-03
WO2001090716A2 (fr) 2001-11-29
AU2001266609A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
Zhou et al. Quantum dots applied to methodology on detection of pesticide and veterinary drug residues
EP1062511B1 (fr) Techniques de dosage immunologique mettant en application une diffusion raman augmentee en surface
US6013802A (en) Fluorescent conjugates of metal-chelating nitrogen heterocycles
US7767821B2 (en) Long wavelength thiol-reactive fluorophores
US7745229B2 (en) Chemoselective fluorgenic molecular linkers and methods for their preparation and use
JPH09505888A (ja) 化学発光アッセイ用金属キレート含有組成物
JP2003532878A (ja) バイオセンシングに対する蛍光ポリマー−ｑｔｌアプローチの改良
EP2318051A2 (fr) Marqueurs diagnostiques in vitro comprenant des nanoparticules de carbone et trousses
WO2008018894A2 (fr) Chimiodétecteurs à base de points quantiques et composés oxazine
JP2009513766A (ja) 新規な蛍光染料およびその使用
WO2007125300A1 (fr) Points quantiques permettant de detecter des signaux de luminescence en meme temps que des signaux raman
US20070184559A1 (en) Method and compounds for the fluorescent labelling of biomolecules and polymer particles
CA2336904A1 (fr) Nouveaux chelates fluorescents aux lanthanides
CN111675674A (zh) 一种aie分子及其合成方法
US20030129591A1 (en) Linker arms for nanocrystals and compounds thereof
WO2001090717A2 (fr) Bras de liaison pour nanocristaux et composes correspondants
US20050192430A1 (en) Linker arms for nanocrystals and compounds thereof
JP3538277B2 (ja) 免疫測定用標識試薬及びそれに用いる蛍光性化合物及び錯体、及びそれらを用いる生物物質の免疫測定法
US20030129590A1 (en) Linker arms for nanocrystals and compounds thereof
US6809220B2 (en) Trityl-type compounds and their use
KR100979463B1 (ko) 니켈 결합 양자점을 이용한 히스티딘 표지 단백질의검출방법
JP6924780B2 (ja) 結合アッセイのバックグラウンド遮断剤
Huang et al. RETRACTED: The application of quantum dots as fluorescent label to glycoarray
EP1090007A2 (fr) Nouveaux composes
Demchenko Design and properties of fluorescence reporters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP